{
  "name": "Egetis Therapeutics",
  "slug": "egetis-therapeutics",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-05T23:41:59Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-05: stängning 6.74, volym 803369",
  "mfn_status": "resolved_no_reports",
  "mfn_count": 0,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/egetis-therapeutics/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-04-29",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "Kvartalsrapport Q1 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6eed573445c5007fad22497e9ea6e15a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709",
            "date": "2026-04-29",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf",
            "text_chars": 46392,
            "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 46392
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-03-24",
        "title": "Årsredovisning 2025",
        "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bd422734e05445b3d94aa01527b8e5ec3&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a",
            "date": "2026-03-24",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf",
            "text_chars": 315393,
            "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 176425
              },
              {
                "number": 2,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 138966
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-26",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "Bokslutskommuniké januari-december 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b44b80c3eb35069e5d3ef27619cf43fbf&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53",
            "date": "2026-02-26",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf",
            "text_chars": 49800,
            "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 49800
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-11-25",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "Kvartalsrapport Q3 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2bc7bcb707477cbbca001cd7f5bbfe7f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4",
            "date": "2025-11-25",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "Q3_2025_Report_SE_Final_251125.pdf",
            "text_chars": 50087,
            "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 50087
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-21",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "Kvartalsrapport Q2 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bdc02099a782352223cdc8a80791bb306&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988",
            "date": "2025-08-21",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf",
            "text_chars": 9423,
            "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 9423
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-04-30",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "Kvartalsrapport Q1 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b04407352577b944f1db775fbba6cc0a5&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf",
            "date": "2025-04-30",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf",
            "text_chars": 322374,
            "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 177753
              },
              {
                "number": 2,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-002.html",
                "chars": 144619
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-11",
        "title": "Årsredovisning 2024",
        "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5e86dbf640e2107ef0195a10490f2570&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f",
            "date": "2025-04-11",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf",
            "text_chars": 322374,
            "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 177753
              },
              {
                "number": 2,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 144619
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-26",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "Bokslutskommuniké januari-december 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b54c8861ab69dd5eb6b82cb4c09c9ecfd&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3",
            "date": "2025-02-26",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf",
            "text_chars": 60074,
            "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 60074
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-11-08",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "Kvartalsrapport Q3 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3079030691d8cfcfff1aa18663986305&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07",
            "date": "2024-11-08",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf",
            "text_chars": 63859,
            "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 63859
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-08-22",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "Kvartalsrapport Q2 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf3afba6a33edcdc6e6188bc8f6cfd633&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1",
            "date": "2024-08-22",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "Q2_2024_Report_SE_240822_Final.pdf",
            "text_chars": 11615,
            "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 11615
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-03",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "Kvartalsrapport Q1 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b5d81534397dc40acd5a145f1bab09c3c&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc",
            "date": "2024-05-03",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "Q1_2024_Report_SE_240502_Final3.pdf",
            "text_chars": 18247,
            "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 18247
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-04-15",
        "title": "Årsredovisning 2023",
        "original_title": "Publicering av Egetis Therapeutics årsredovisning för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bf825d303bbb3f339d86185713acda286&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e",
            "date": "2024-04-15",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf",
            "text_chars": 318947,
            "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 176539
              },
              {
                "number": 2,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 142406
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-22",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "Bokslutskommuniké januari-december 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bda8425e5dd15751763854e309cc2a802&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6",
            "date": "2024-02-22",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf",
            "text_chars": 12027,
            "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 12027
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-11-08",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "Kvartalsrapport Q3 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4b37225e0947f3a95bc7db73dc9508a9&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696",
            "date": "2023-11-08",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "Q3_2023_Report_SE_231108_Final.pdf",
            "text_chars": 14617,
            "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 14617
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-22",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "Kvartalsrapport Q2 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b29970ae3290eb0fee17334f1634fc4f4&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2",
            "date": "2023-08-22",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf",
            "text_chars": 12420,
            "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 12420
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-04-26",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "Delårsrapport januari-mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b8eda6e67ac908da1643016b7ac20eb8f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182",
            "date": "2023-04-26",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf",
            "text_chars": 11347,
            "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c",
            "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 11347
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "Egetis Therapeutics",
    "identity": {
      "issuer": "Egetis Therapeutics AB (publ)",
      "lei": "549300RZCKGWRUBPMY22",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 41,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Egetis Therapeutics",
      "query": "Egetis Therapeutics AB (publ)",
      "candidate_count": 346
    },
    "period": {
      "from": "2024-08-04",
      "to": "2026-08-04",
      "years": 2
    },
    "generated_at": "2026-08-04T10:37:02Z",
    "insider": {
      "transactions": 40,
      "all_export_rows": 40,
      "acquisitions": 31,
      "disposals": 9,
      "other": 0,
      "acquisition_value_sek": 5046597.27,
      "disposal_value_sek": 8852298.97,
      "characters": {
        "Avyttring": 9,
        "Förvärv": 31
      }
    },
    "short_selling": {
      "aggregate_percent": 0.78,
      "current_public_positions": 0,
      "historical_changes": 0,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [
    "MFN fallback: resolved_no_reports"
  ],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "egtx",
      "instrument_id": "TX868732",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/egtx?id=TX868732"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "Egetis Therapeutics",
      "expected_name": "Egetis Therapeutics",
      "match_score": 100.0,
      "slug": "egetis-therapeutics",
      "url": "https://mfn.se/all/a/egetis-therapeutics",
      "metadata": {
        "country": "Sverige",
        "list": "Mid Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://career.modularfinance.se"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX868732",
      "asset_class": "SHARES",
      "isin": "SE0003815604",
      "symbol": "EGTX",
      "company": "Egetis Therapeutics",
      "market": null,
      "last_sale_price": "SEK 6.74",
      "time_as_of": "2026-08-05"
    },
    "finansinspektionen": {
      "issuer": "Egetis Therapeutics AB (publ)",
      "lei": "549300RZCKGWRUBPMY22",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 41,
      "score": 118.0,
      "status": "resolved",
      "requested_company": "Egetis Therapeutics",
      "query": "Egetis Therapeutics AB (publ)",
      "candidate_count": 346
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a6942a777fa930bf7ba2a66e9c6e7d709",
      "date": "2026-04-29",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "Q1_2026_Report_SE_Final_29Apr26.pdf",
      "text_chars": 46392,
      "sha256": "ff9f5cc745ae70cf8c049a2abd6c76b101978569d7298748622e6f886ff4f589",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 46392
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a206b29851971e83a5e68d755cca5175a",
      "date": "2026-03-24",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "SE_Egetis_Arsredovisning_2025_Final.pdf",
      "text_chars": 315393,
      "sha256": "206190893364d309d49e76354c86f46872e1ddc1eda7ff77c2d41d92821021f9",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 176425
        },
        {
          "number": 2,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 138966
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/afb4ad5faeb596fcdd65881be25fbee53",
      "date": "2026-02-26",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "Q4_2025_Report_SE_Final_26Feb26.pdf",
      "text_chars": 49800,
      "sha256": "1bde4c42b0bb53c1c079966ee502f2bfe91ba95d1277103e83b2ac60b2c45362",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 49800
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/abb89c7e3bfb497221a55896c76316fd4",
      "date": "2025-11-25",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "Q3_2025_Report_SE_Final_251125.pdf",
      "text_chars": 50087,
      "sha256": "b49416f6b530d87e6fa92f0709ba4418aa8f662bf4d10ce866e085ae271edc8f",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 50087
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac44f8c6ae3726c1abdc80e5151a80988",
      "date": "2025-08-21",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "Q2_2025_Report_SE_21Aug25_Final2.pdf",
      "text_chars": 9423,
      "sha256": "1c00dfb9aa39bd12a0d6a12a54d34af3bd191f6215f3fadd5c09216425e94ed0",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 9423
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://storage.mfn.se/6c145720-d2d9-4d4e-a1d2-0c306524c482/se-egetis-arsredovisning-2024-final-11apr24.pdf",
      "date": "2025-04-30",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "se-egetis-arsredovisning-2024-final-11apr24.pdf",
      "text_chars": 322374,
      "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 177753
        },
        {
          "number": 2,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-002.html",
          "chars": 144619
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a46c706f2daf09ea8e3384d4049251d6f",
      "date": "2025-04-11",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "SE_Egetis_Arsredovisning_2024_Final_11Apr24.pdf",
      "text_chars": 322374,
      "sha256": "db4524eb5ecab1bbd5836cc9200d653305a7c8723edd7c542fadd6f305a9076f",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 177753
        },
        {
          "number": 2,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 144619
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ae9ee14b96c878a9a47db936acdbb5aa3",
      "date": "2025-02-26",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "Q4_2024_Report_SE_26Feb25_FINAL.pdf",
      "text_chars": 60074,
      "sha256": "7a4a10a1d1c6c88068236b0ffa80bd9650e4cae88f80b5c1a62e4ba8e0e5f6d3",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 60074
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a00e566ae0ea10c2f34e55f9ae3dbfc07",
      "date": "2024-11-08",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "Q3_2024_Report_SE_08Nov24_Final.pdf",
      "text_chars": 63859,
      "sha256": "a1a8d360bc3da5e4da946ec8c2702fde4f5eeb447605dd895ed6f93c7a7383f1",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 63859
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ad971c0227867ee160499400f812e4bc1",
      "date": "2024-08-22",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "Q2_2024_Report_SE_240822_Final.pdf",
      "text_chars": 11615,
      "sha256": "51e1b382f5a02633c6cfe88c874df8987bf950c55b1a47f1ff17d3eedb18e663",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 11615
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/abd668147eaa3e410da42161261df85bc",
      "date": "2024-05-03",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "Q1_2024_Report_SE_240502_Final3.pdf",
      "text_chars": 18247,
      "sha256": "579b9bc37fc30053cc5539be29354a48a33bfbc0341d9e37ee3c4d79e11eaaae",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 18247
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af3cbeb2a13b2252df08cedc14f66f84e",
      "date": "2024-04-15",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "SE_Egetis_Arsredovisning_2023_15apr_Final.pdf",
      "text_chars": 318947,
      "sha256": "c13ece608fcfbaf3d8bdc4f7c9d4b18ab9bdbcd5a2816c389909574d7516621b",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 176539
        },
        {
          "number": 2,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 142406
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a12a7619ddbbcdd6dbc09b8b68c4559b6",
      "date": "2024-02-22",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "Q4_2023_Report_SE_22Feb24_Final.pdf",
      "text_chars": 12027,
      "sha256": "c74b0310aa944a883fbfde5f82b17babc92c1a2544b19825afe7c951fa796187",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 12027
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/af10655b0f42a9aca5c888135b38d3696",
      "date": "2023-11-08",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "Q3_2023_Report_SE_231108_Final.pdf",
      "text_chars": 14617,
      "sha256": "6b974f7a141056849b25d4455bd5a97735ff5a76dd998261d1efdb488ac1bd86",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 14617
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a7bfb1997a92a6956a70d8d6fec6bdca2",
      "date": "2023-08-22",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "Q2_2023_Report_SE_2023_08_22_Final.pdf",
      "text_chars": 12420,
      "sha256": "bb0886b68a2e034010940ab25a0ffc98402fc63c1f316c59cfb58a860ff10a0c",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 12420
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a54a3c90b056400d051dbf7b09b8f0182",
      "date": "2023-04-26",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "Q1_2023_Report_SE_26Apr23_FINAL.pdf",
      "text_chars": 11347,
      "sha256": "7bd65deddf5154ea59d06116f0426bab167e1bec38b054a309421d852aabbe0c",
      "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 11347
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/egetis-therapeutics",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 14359,
      "sha256": "62dde7ee36b2003d474e4d63ec3d16f38c2a64ed2f14f5a1ac92cf4297e44733",
      "url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/egetis-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 14359
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/egetis-therapeutics/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/egetis-therapeutics/market/history.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/egetis-therapeutics/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/egetis-therapeutics/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/instrument.json"
    },
    {
      "label": "SEC sammanfattning JSON",
      "url": "/company/egetis-therapeutics/market/sec-summary.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/sec-summary.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/egetis-therapeutics/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/egetis-therapeutics/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/egetis-therapeutics/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": true,
    "status": "retrieved",
    "captured_at": "2026-08-02T20:09:39Z",
    "view_count": 4,
    "url": "/company/egetis-therapeutics/morningstar",
    "path": "D:\\Web\\aktieanalys\\public\\company\\.egetis-therapeutics.tmp\\morningstar",
    "files": [
      "index.html",
      "summary.txt",
      "screenshot.png"
    ]
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/egetis-therapeutics/finansinspektionen",
    "transaction_count": 40,
    "aggregate_short_percent": 0.78,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/egetis-therapeutics/llms.txt",
  "json_url": "/company/egetis-therapeutics/company.json",
  "document_index_url": "/company/egetis-therapeutics/documents.json",
  "absolute_url": "https://spela.port0.org/company/egetis-therapeutics"
}